Omaha, Neb., USA - November 6, 2014, Omaha, Neb., USA - Transgenomic, a biotechnology company, announced that CFO and executive vice president Mark Colonnese has resigned.
Article continues below
Mr. Colonnese has nearly 30 years of experience in leading business growth and financial strategies for life sciences companies. He served as Executive Vice President, Commercial Operations and Chief Financial Officer at Salutria Pharmaceuticals, LLC.
Prior to that, Mr. Colonnese served as Executive Vice President, Commercial Operations at AtheroGenics, Senior Vice President and Chief Financial Officer at Medaphis Corporation, and has also held executive positions at Applied Analytical Industries, and Schering-Plough Corporation.
Mr. Colonnese holds an M.B.A. from Fairleigh Dickinson University, a B.S. from Ithaca College, and is a Certified Public Accountant.
Paul Kinnon, Transgenomic's President and Chief Executive Officer, will assume the role of Interim Chief Financial Officer.
Mr. Kinnon was appointed President and Chief Executive Officer of Transgenomic in September, 2013. He has more than 20 years of global leadership experience in innovative life science and diagnostics companies.
Mr. Kinnon provided consulting services to the life science sector as a Partner at Arch Global Research. He was President, CEO and a Director of ZyGEM, Vice President & General Manager Environmental Diagnostics at Invitrogen, and Vice President of Global Strategic Alliances at Invitrogen.
Mr. Kinnon was Vice President of Sales & Marketing at Guava Technologies, Vice President of Sales, and was European Manager for Cellomics. He was Sales & Marketing Director at Porvair Sciences and he held marketing and sales positions of increasing responsibility in a number of technology-based companies. He began his career as an analytical chemist at a predecessor company of GlaxoSmithKline.
Leon Richards, Transgenomic's Corporate Controller, will take on additional responsibilities as Chief Accounting Officer for Transgenomic.
Mr. Richards joined the financial group at Transgenomic in 2012. Previously, he served as Corporate Controller and Chief Accounting Officer at Baldwin Technology Company. ■